Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Grassley Mows Down FDA Handling Of ADHD Drug Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

Adverse events need a “comprehensive review,” Senate Finance Committee Chairman says, questioning FDA’s approach to advisory committees.

You may also be interested in...

Cephalon Sparlon For ADHD To Get Psychopharm Committee Review

The March 23 review of the new indication for modafinil, currently marketed as Provigil for narcolepsy, will likely focus on safety differences compared to other ADHD drugs.

FDA Issues Strattera Public Health Advisory On Suicidal Thinking

Advisory alerts physicians to the risk of suicidal thinking in children and adolescents related to use of Eli Lilly's ADHD therapy atomoxetine.

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts